According to TechSci Research report, “Global Colorectal Cancer Therapeutics Market- Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2019-2029”, the Global Colorectal Cancer Therapeutics Market has valued at USD 11.10 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.20% through 2029. This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and strengthen their position in the market.
Advances in diagnostic technologies have significantly improved the early detection, diagnosis, and monitoring of colorectal cancer. These technologies have a profound impact on the field of colorectal cancer therapeutics. Colonoscopy and Flexible Sigmoidoscopy: These endoscopic procedures have become more precise and less invasive, allowing for the direct visualization and biopsy of colorectal tumors, as well as the removal of polyps before they become cancerous.
CT Colonography (Virtual Colonoscopy) is a non-invasive imaging technique that uses computed tomography to produce detailed 3D images of the colon, aiding in the detection of polyps and tumors. MRI scans can provide detailed images of the colon and rectum, helping in the staging of colorectal cancer and the assessment of tumor extent. Stool DNA Testing, such as the Cologuard test, detects DNA changes associated with colorectal cancer in stool samples.
They are non-invasive and can be used for early detection. Blood tests, such as the carcinoembryonic antigen (CEA) test, help in monitoring cancer progression and response to treatment. Liquid biopsies involve the analysis of circulating tumor DNA (ctDNA) in the bloodstream. They can detect genetic mutations, alterations, and the presence of cancer, offering a non-invasive means of early diagnosis and treatment monitoring.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on “ Global Colorectal Cancer Therapeutics Market” @ https://www.techsciresearch.com/report/colorectal-cancer-therapeutics-market/21090.html
In January 2023, Takeda has announced an exclusive licensing agreement with HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited, for the continued development and commercialization of fruquintinib outside of mainland China, Hong Kong, and Macau. Fruquintinib, which received approval in China in 2018, is a potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, 2, and 3.
It is orally administered and holds promise for the treatment of refractory metastatic colorectal cancer (CRC) across different biomarker statuses. Notably, positive results from the FRESCO-2 Phase 3 clinical trial, presented at the European Society for Medical Oncology (ESMO) Congress in September 2022, demonstrated that fruquintinib improved overall survival in patients with metastatic CRC and exhibited a generally well-tolerated safety profile.
Immunotherapy response variability is a challenge in the global colorectal cancer therapeutics market. The variability in patient response to immunotherapy in the context of colorectal cancer is influenced by several factors, and it presents challenges for treatment efficacy. Colorectal cancer is characterized by significant tumor heterogeneity, with various genetic and molecular subtypes. Not all tumors have the same immunogenicity, and this can lead to differing responses to immunotherapies.
While some colorectal cancer patients respond well to immunotherapy, the identification of reliable predictive biomarkers for treatment response, such as PD-L1 expression or MSI-high status, is not always straightforward. Not all patients with these biomarkers respond, and some without them may still benefit. The composition of the tumor microenvironment, including the presence of immune cells, the immunosuppressive effect of certain cell types, and the expression of immune checkpoint proteins, can influence treatment response.
Tumors with an immune-suppressed microenvironment may be less responsive to immunotherapies. A significant portion of colorectal cancer cases is microsatellite stable, and they often exhibit a reduced response to immunotherapies compared to MSI-high tumors. Some tumors develop resistance to immunotherapies over time, limiting the duration of response and leading to treatment failure.
The Global Colorectal Cancer Therapeutics Market is segmented based on Drug Class and by region
Based on the Drug Class, Global Colorectal Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and others. Chemotherapy is a cancer treatment that uses drugs to stop the growth and spread of cancer cells. It is one of the most widely used and effective methods for treating various types of cancer. Chemotherapy is used to target and destroy rapidly dividing and multiplying cancer cells. It can be employed as the primary treatment for cancer, particularly when the cancer has spread or is in advanced stages, or it can be used in combination with other treatments, such as surgery or radiation therapy.
Chemotherapy can have side effects because it affects both healthy and cancerous cells. Common side effects may include nausea, vomiting, fatigue, hair loss, anemia, lowered immunity, and digestive issues. The severity and specific side effects can vary depending on the drugs used and the individual’s tolerance. The duration of chemotherapy treatment varies based on the type and stage of cancer. It may involve several cycles of treatment, each followed by a rest period to allow the body to recover.
Based on Region, North America held the largest share of the Global Colorectal Cancer Therapeutics Market. There are well-established colorectal cancer awareness and screening programs in North America. Efforts to promote early detection and regular screenings have contributed to a higher proportion of patients being diagnosed at earlier stages when treatments are more effective.
North America is home to a significant portion of the global pharmaceutical industry. Major pharmaceutical companies based in the United States and Canada invest heavily in research and development for cancer therapeutics, including colorectal cancer treatments. Governments and federal agencies in North America provide substantial support and funding for cancer research, including colorectal cancer. This support helps drive advancements in treatment options. North American companies often play a leadership role in the global pharmaceutical and biotechnology markets. This allows them to influence and shape the global colorectal cancer therapeutics market significantly.
Some of the major companies operating in the Global Colorectal Cancer Therapeutics Market include:
- Amgen, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Elli and Lilly Co.
- Merck & co., Inc.
- F. Hoffmann-La Roche Ltd.
- Sanofi SA
To Download FREE Sample Pages of this Report📥 @ https://www.techsciresearch.com/sample-report.aspx?cid=21090
Customers can also request 10% free customization on this report.
“Certain areas, particularly in North America, are projected to exert significant demand for Colorectal Cancer Therapeutics. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhancing the overall well-being of people each year, are expected to contribute to a remarkable growth of the Global Colorectal Cancer Therapeutics Market in the forecast period,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.
Colorectal Cancer Therapeutics Market by Drug Class (Chemotherapy, Immunotherapy, others), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated the future growth potential of the Global Colorectal Cancer Therapeutics Market and provides statistics & information on the market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the Global Colorectal Cancer Therapeutics Market.
You may also read:
Pharmacokinetics services market – A Comprehensive Report [2029]
Table of Content-Colorectal cancer therapeutics market
- Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
- Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
- Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
- Voice of Customer
- Clinical Trials Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
- Global Colorectal Cancer Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Chemotherapy, Immunotherapy, others)
6.2.2. By Region
6.2.3. By Company (2023)
6.3. Market Map
- Asia Pacific Colorectal Cancer Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Colorectal Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
